Jonathan McNeill - Jan 9, 2023 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Senior Vice President of Business Development
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Stock symbol
DYN
Transactions as of
Jan 9, 2023
Transactions value $
-$348,836
Form type
4
Date filed
1/11/2023, 03:56 PM
Previous filing
Dec 13, 2022
Next filing
Jan 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Sale -$349K -30.2K -30.84% $11.57 67.6K Jan 9, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.12 to $11.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F3 Includes 67,490 unvested RSUs.

Remarks:

Senior Vice President of Business Development